10-Q quarterly report · filed Oct 29, 2026

Biohaven Ltd. (BHVN) Q3 2026 10-Q Quarterly Report

Short answer

Biohaven Ltd. (BHVN) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$129M
+25.5% YoY · +5.8% QoQ
EPS (diluted)
−$0.85
+47.9% YoY · +7.6% QoQ

Source: XBRL data from the Biohaven Ltd. (BHVN) Q3 2026 10-Q on SEC EDGAR. USD.

Biohaven Ltd. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY, with no product sales
  • Net loss $129.3M vs $173.4M YoY, operating margin not meaningful due to no revenue
  • Highest R&D spend: BHV-1400 at $10.1M, lowest: BHV-2100 and BHV-2110 at $(1.2)M
  • Cash and equivalents $95.8M plus marketable securities $65.4M; operating cash use $341.9M year-to-date
  • Outlook: RISE 3 topline results on track for second half of 2026; BHV-7000 enrollment paused under partial clinical hold

Risk Factors

  • New Ono collaboration risk: October 2026 license covers MoDE™ degraders in Japan, South Korea, Taiwan, and ASEAN
  • Most materially updated financial risk: no committed external funding beyond potential SKBP and Ono payments
  • Regulatory and compliance risk: SKBP HSR waiting period expired October 28, 2026, but remaining closing conditions persist
  • Operational risk: SKBP controls development resources for Kv7 products, including opakalim
  • Financial risk: SKBP agreement includes $400.0 million upfront and up to $150.0 million milestone payments at risk

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Biohaven Ltd. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.